# Time to first cardiovascular hospitalization after guideline-based treatment optimization: A multicenter retrospective cohort study in northwest Ethiopia

**Authors:** Getachew Yitayew Tarekegn, Abel Temeche Kassaw, Tilaye Arega Moges, Samuel Agegnew Wondm, Samuel Berihun Dagnew, Tigabu Eskeziya Zerihun, Desalegn Addis Mussie, Fasil Bayafers Tamene, Abaynesh Fentahun Bekalu, Woretaw Sisay zewdu

PMC · DOI: 10.1016/j.ijcrp.2026.200607 · International Journal of Cardiology. Cardiovascular Risk and Prevention · 2026-02-17

## TL;DR

This study found that nearly half of patients in Ethiopia were hospitalized for cardiovascular issues within a year, highlighting the need for better treatment and follow-up.

## Contribution

The study identifies specific predictors of early cardiovascular hospitalization in a low-resource setting, offering actionable insights for targeted interventions.

## Key findings

- Nearly half (46.4%) of patients were hospitalized within 12 months of treatment optimization.
- Independent predictors included partial/no guideline therapy, comorbidities, heart failure, and lack of follow-up.
- Median time to hospitalization was 100 days, with most admissions occurring within 3–4 months.

## Abstract

Cardiovascular hospitalization is a leading cause of morbidity and mortality, especially in low-resource settings. Evidence on predictors in Ethiopia is limited, hindering targeted interventions.

To assess the incidence and predictors of first cardiovascular hospitalization within one year of treatment optimization in Northwest Ethiopia.

A retrospective cohort study was conducted at three tertiary hospitals. Baseline demographic, clinical, and treatment data were extracted from medical records of patients receiving optimized cardiovascular therapy. Multivariate Cox proportional hazards regression with robust standard errors identified independent predictors of first hospitalization.

Among 470 patients, 218 (46.4%) were hospitalized within 12 months; median time to first admission was 100 days (IQR 55–160). Independent predictors of shorter hospitalization-free survival included partial or no guideline-directed medical therapy (HR 1.71, 95% CI: 1.30–2.25), Charlson Comorbidity Index ≥3 (HR 1.62, 95% CI: 1.25–2.10), heart failure with reduced ejection fraction (HR 1.46, 95% CI: 1.10–1.94), chronic kidney disease (HR 1.41, 95% CI: 1.02–1.95), current smoking (HR 1.40, 95% CI: 1.01–1.95), low physical activity (HR 1.35, 95% CI: 1.03–1.77), age ≥65 years (HR 1.36, 95% CI: 1.05–1.76), and absence of a scheduled follow-up plan (HR 1.60, 95% CI: 1.18–2.16).

Nearly half of patients experienced hospitalization within one year, mostly within 3–4 months. Ensuring guideline-directed therapy, structured follow-up, and addressing modifiable risk factors may reduce early cardiovascular admissions in low-resource settings.

## Linked entities

- **Diseases:** heart failure (MONDO:0005252), chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** REN (renin) [NCBI Gene 5972] {aka ADTKD4, HNFJ2, RTD}, NPPB (natriuretic peptide B) [NCBI Gene 4879] {aka BNP, Iso-ANP}, MME (membrane metalloendopeptidase) [NCBI Gene 4311] {aka CALLA, CD10, CMT2T, NEP, SCA43, SFE}, SLC5A2 (solute carrier family 5 member 2) [NCBI Gene 6524] {aka SGLT2}
- **Diseases:** Obesity (MESH:D009765), arrhythmia (MESH:D001145), chest pain (MESH:D002637), cardiomyopathies (MESH:D009202), COPD (MESH:D029424), stroke (MESH:D020521), frailty (MESH:D000073496), Comorbidity (MESH:D004194), volume overload (MESH:D019190), dyslipidemia (MESH:D050171), Acute Coronary Syndrome (MESH:D054058), dyspnea (MESH:D004417), ischemic (MESH:D002545), vascular disease (MESH:D014652), diabetes (MESH:D003920), edema (MESH:D004487), CKD (MESH:D051436), Ischemic Attack (MESH:D002546), kidney dysfunction (MESH:D007674), Heart Failure (MESH:D006333), Cardiac function and organ dysfunction (MESH:D006331), ventricular tachycardia (MESH:D017180), systolic heart failure (MESH:D054143), CCI (MESH:C566784), death (MESH:D003643), hypertension (MESH:D006973), Left Ventricular Hypertrophy (MESH:D017379), CVDs (MESH:D002318), Myocardial infarction (MESH:D009203), GDMT (MESH:D016609), Atrial Fibrillation (MESH:D001281), post-MI (MESH:D000094025), Ischemic heart disease (MESH:D017202), ACS (MESH:D000168)
- **Chemicals:** aldosterone (MESH:D000450), ferrous sulfate (MESH:C020748), ARNI (-)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12938863/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12938863/full.md

## References

33 references — full list in the complete paper: https://tomesphere.com/paper/PMC12938863/full.md

---
Source: https://tomesphere.com/paper/PMC12938863